Atorvastatin, a synthetic HMG-CoA reductase inhibitor (HMGRI), has demonstrated
significant lipid-lowering effects in previous clinical trials. This ongoing, open-label …

Synopsis Atorvastatin is a synthetic HMG-CoA reductase inhibitor which lowers plasma
cholesterol levels by inhibiting endogenous cholesterol synthesis. It also reduces …

In this 2-year study, 787 patients with hypercholesterolemia received either atorvastatin 10
mg to 80 mg/day (623 patients) or lovastatin 20 mg to 80 mg/day (164 patients). Patients …

A rapid and sensitive high-performance liquid chromatographic method for the
determination of atorvastatin (CAS 134523-00-5) in plasma was developed in this study …

Background: Simvastatin 40 to 80 mg/d has been found to increase high-density lipoprotein
cholesterol (HDL-C) levels significantly more than atorvastatin at equipotent doses (ie, 20 …

Atorvastatin is a synthetic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor. In dosages of 10 to 80 mg/day, atorvastatin reduces levels of total cholesterol, low …

Background: Cardiovascular disease (CVD) is the leading cause of death in India and
worldwide. Hypercholesterolemia plays a pivotal role in atherogenesis which gave rise to …

A liquid chromatographic/mass spectrometric method to quantitate atorvastatin (AT) and its
active metabolites ortho-hydroxy (o-AT) and para-hydroxy (p-AT) atorvastatin in human, dog …

The results of numerous long-term, randomized trials show that statins significantly decrease
the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The …